All News
Secukinumab promise in PMR is real
Choice is not just good, it is often necessary, and secukinumab promises just that in both PMR and GCA.
Read Article
#EULAR2025 Abstr#OP0074 Manufacturing time for CAR-T can be a hindrance. Preliminary study (N=10 #SLE patients) of CD19/BCMA dual-targeting CAR-T developed on the novel FasTCAR-T platform with next-day manufacturing, showed promising efficacy and safety signals @RheumNow https://t.co/bgF04qe9C7
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Worried about cancer risk with ts/bDMARDs in RA?
Real-world data from over 4,600 patients says: don’t be. No increased risk of cancer (incl. NMSC) for JAKi, IL6i, CD20i, or CTLA4-A vs TNFi in long-term registry follow-up.
Abstract#OP0065
@RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
Early intensive therapy in PsA.
STAMP RCT in early PsA:
•ACR50 at 3mo: 43% (early secukinumab) vs 22% (SoC)
•MDA at 3mo: 48% vs 25%
•PASI90 at 3mo: 60% vs 22%
By 12months: outcomes similar, but early secukinumab led to faster control and fewer therapy escalations. https://t.co/TKa5z24NQX
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Can lowering serum urate also lower CV risk? In >116k patients w/ #gout, achieving SU <360 µmol/L in 12m ↓ 5yr MACE risk (HR 0.89, pooled Δsurvival +1.4%). Greater effect in >65s. Gout management = CV prevention?
@RheumNow #EULAR2025 #OP0005 https://t.co/NRAerUBemN
Mrinalini Dey DrMiniDey ( View Tweet)
STAMP RCT early SEC vs. SoC 120pts
Retention 58% vs 30%
ACR 20, 50, 70 and MDA: better outcome at Month 3 but no difference at Month 6
Dactylitis no difference
Of note here SoC was a tight T2T strategy!
@RheumNow #OP0092 #EULAR2025 https://t.co/8zHs5CRFV5
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
What happens in pre-RA when you stop #abatacept after 1 yr Rx
At 6 yrs approx 60% on #Placebo
V
50% who initially got #ABA
Prolonged damped effect of development of #RA
NNT for 1 yr is ~10 with a range as low as 6
#EULAR2025 @RheumNow @eular_org
Abst#OP0004 https://t.co/1VOEaZ00Ia
Links:
Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Abstr#OP0075 Interesting that even among #SLE patients, no single definition of “Lupus Under Control” reached at least 50% agreement. Live Poll with clinicians in the room further highlighted the discordant. More works are needed - to help tailor management @RheumNow https://t.co/WzkQkMD23i
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 Abstr#OP0032 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 5 #SLE patients in Phase 1. Advantages over autologous/allogenic:
-No apheresis
-No conditioning chemo
-Shorter hospital stays ~3days
-Ability to redose in partial responder
@RheumNow https://t.co/qimC94pVU1
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Should we start strong in PsA?
In the SPEED RCT (Coates et al), both early TNFi and combo csDMARDs outperformed step-up care in moderate-severe PsA. TNFi showed the most sustained benefit through 48w.
Abstract#OP0089
@RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
First FcRn inhibitor in #IIM: In #ALKIVIA, SC efgartigimod PH20 improved TIS vs placebo at 24wks (50.45 vs 35.65, p=0.0004), with faster time to TIS≥20 (30 vs 71.5d) & TIS≥40 (113d vs NE). More major responders too (TIS>60: 34% vs 9.5%).
@RheumNow #EULAR2025 #OP0002 https://t.co/75BfbXoVpL
Mrinalini Dey DrMiniDey ( View Tweet)
Muscle biopsies form 3 treatment-naïve juvenile dermatomyositis (JDM) finds transcriptomic evidence of mitochondrial dysfunction consistently in JDM muscle, independent of interferon-driven inflammation. Treating mitochondrial dysfunction may improve JDM outcomes https://t.co/u5tMhT23si
Dr. John Cush RheumNow ( View Tweet)
How to patients with rheumatic diseases consume online health information?
78% used internet for health information
50% use it atleast a month
66% found online information superior
41% used social media!
80% using it to find treatment optio ns!
@rheumnow #EULAR2025 https://t.co/diMCloFFVF
Links:
Bella Mehta bella_mehta ( View Tweet)
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 @RheumNow https://t.co/vqZajY0nUp
David Liew drdavidliew ( View Tweet)
Platelet rich plasma in knee #OA! They asked this to #ChatGPT ...
Whatever is out there on the internet will contaminate responses which pts rely on..:(
@rheumnow #EULAR2025 https://t.co/stlbhHp3zp
Links:
Bella Mehta bella_mehta ( View Tweet)
Treatment of MAS, or the bête noire in Still's disease, presented at the Plenary session by Peter Nigrovic
#Plenary room
#EULAR2025
@RheumNow https://t.co/S4SG2VflNg
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#AI can be a valuable tool, but needs to be reliable. Lupus100 and #lupusGPT created with vetted sources,
#Easylupus is condensed, even more easy to read
It's better to ask your patients to use it as a reliable source!
#EULAR2025 @RheumNow https://t.co/FbYYm1dB8E
Links:
Bella Mehta bella_mehta ( View Tweet)
Debuting Fishbowl sessions at #EULAR2025 🔄💊
Lively audience engaging session in A1 on how drug prices influence treatment decisions; real-world tensions between cost, access, & physician autonomy. Transparent, interactive, and packed!
@RheumNow | Location: A1 | #EULAR2025 https://t.co/jVbviLuTZK
Jiha Lee JihaRheum ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty
Dr. John Cush RheumNow ( View Tweet)
#MTX in new #PMR?!
RCT of #MTX was negative in early #PMR - no effect on #steroid #tapering
ACR24 #1697
At #EULAR2025
👇
+RCT of #methotrexate in PMR <8wks #steroids #Rx MTX 25 mg/wk v #placebo
N=64
⬆️GC remission ✅80% v 46%
⬇️relapse w MTX
🤔
Abst0064 @RheumNow #EULAR2025
Janet Pope Janetbirdope ( View Tweet)
